Acquisition2025-10-29confirmed

Thermo Fisher Scientific Inc. × Clario Holdings, Inc.

Thermo Fisher Scientific announced a definitive agreement to acquire Clario from a shareholder group for $8.875 billion in cash at closing. [38] The deal also includes a $125 million payment in January 2027 and up to $400 million in performance-based earn-outs. [50] The acquisition is intended to enhance Thermo Fisher's drug development capabilities by integrating Clario's platform for collecting and managing clinical trial endpoint data. [34, 50]

Price paid
$8.9B
asset price, paid once
Losing bid
Per unit
295833.3333
$ / clinical trials powered

The asset

The acquisition of Clario, a provider of endpoint data solutions and data intelligence technology for clinical trials. [38, 54]

  • 30k clinical trials powered

The record

Seller status
Going concern
Sector
Clinical trial data solutions
Modalities
clinical_trial_data, patient_reported_outcomes, platform_technology
Jurisdiction
US
Personal data
Clario's platform manages clinical evidence, implying adherence to strict regulatory standards like GCP and HIPAA for handling patient information, though specific de-identification methods are not detailed in the acquisition announcements.

What it means if you hold data

This major acquisition underscores the strategic importance of owning the data infrastructure that underpins clinical trials. By acquiring Clario, Thermo Fisher gains control over a critical data collection and intelligence platform that has supported a high percentage of recent FDA and EMA drug approvals, positioning itself as an end-to-end partner in drug development.

Sources